Considerations for the use of imaging tools for phase II treatment trials in oncology

Clinical Cancer Research

Volumn 15, Issue 6, 2009, Pages 1891-1897

  Shankar, Lalitha K ^a   Van Den Abbeele, Annick ^b   Yap, Jeff ^b   Benjamin, Robert ^c   Scheutze, Scott ^d   FitzGerald, T J ^e  

^a NATIONAL CANCER INSTITUTE   (United States)

^b DANA FARBER CANCER INSTITUTE   (United States)

^c UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^d UNIVERSITY OF MICHIGAN HEALTH SYSTEM   (United States)

^e Quality Assurance Review Center   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; DASATINIB; FLUORODEOXYGLUCOSE; IMATINIB; SORAFENIB; SUNITINIB;

ACCURACY; ARTICLE; CLINICAL TRIAL; COMPUTER ASSISTED TOMOGRAPHY; DRUG RESPONSE; GASTROINTESTINAL STROMAL TUMOR; HUMAN; IMAGE ANALYSIS; MESOTHELIOMA; MOLECULAR IMAGING; NEUROENDOCRINE TUMOR; NUCLEAR MAGNETIC RESONANCE IMAGING; OUTCOMES RESEARCH; PANCREAS TUMOR; PHASE 2 CLINICAL TRIAL; POSITRON EMISSION TOMOGRAPHY; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; REPRODUCIBILITY;

CLINICAL TRIALS, PHASE II AS TOPIC; ENDPOINT DETERMINATION; FLUORODEOXYGLUCOSE F18; GASTROINTESTINAL STROMAL TUMORS; HUMANS; NEOPLASMS; POSITRON-EMISSION TOMOGRAPHY; QUALITY ASSURANCE, HEALTH CARE; SARCOMA;

EID: 63449134205     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-08-2030     Document Type: Article

References (31)

1. Therasse P, Arbuck SG, Eisenhauer EA, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000;92:205-16.
2. Suzuki C, Jacobsson H, Hatschek T, et al. Radiologic measurements of tumor response to treatment: practical approaches and limitations. L Radiographics 2008; 28:329-44.
3. Ratain MJ, Sargent DJ. Optimising the design of phase II oncology trials: the importance of randomisation. Eur J Cancer 2009;45:275-80.
4. Adjei AA, Christian M, Ivy P. Novel designs and endpoints for phase II clinical trials. Clin Cancer Res 2009;15:1866-72.
5. Holdsworth CH, Badawi RD, Manola, JB, et al. CT and PET: early prognostic indicators of response to imatinib mesylate in patients with gastrointestinal stromal tumor. AJR. Am J Roentgenol 2007;189: W324-30.
6. Choi H, Charnsangavej C, Faria SC, et al. Correlation of computed tomography and positron emission tomography in patients with metastatic gastrointestinal stromal tumor treated at a single institution with imati-nib mesylate: proposal of new computed tomography response criteria. J Clin Oncol 2007;25:1753-59.
7. Dhani N,TuD, Sargent DJ, Seymour L, Moore MJ. Alternate endpoints for screening phase II studies. Clin Cancer Res 2009;15:1873-82.
8. McShane LM, Hunsberger S, Adjei AA. Effective incorporation of biomarkers into phase II trials. Clin Cancer Res 2009;15:1898-905.
9. Rubinstein L, Crowley J, Ivy P, LeBlanc M, Sargent D. Randomized phase II designs. Clin Cancer Res 2009;15. In press.
10. Van den Abbeele AD, Badawi RD. Use of positron emission tomography in oncology and its potential role to assess response to imatinib mesylate therapy in gastrointestinal stromal tumors (GIST). Eur J Cancer 2002;38:S60-5.
11. Choi H, Charnsangavej C, Faria SC, et al. CT evaluation of the response of gastrointestinal stromal tumors after imatinib mesylate treatment: a quantitative analysis correlated with FDG PET findings. Am J Roentgenol 2004;183:1619-28.
12. Delaney T, Spiro IJ, Suit HD, et al. Neoadjuvant chemotherapy and radiotherapy for large extremity soft-tissue sarcomas. Int J Radiat Oncol Biol Phys 2003; 56:1117-27.
13. Hawkins DS, Rajendran JG, Conrad EU III, Bruckner JD, Eary JF. Evaluation of chemotherapy response in pediatric bone sarcomas by [F-18]-fluorodeoxy-D- glucose positron emission tomography. Cancer 2002; 94:3277 -84.
14. 18F] Fluorodeoxyglucose positron emission tomography predicts outcome for Ewing sarcoma family of tumors. J Clin Oncol 2005;23:8828-34.
15. Schuetze SM, Rubin BP,Vernon C, et al. Use of positron emission tomography in localized extremity soft tissue sarcoma treated with neoadjuvant chemotherapy. Cancer 2005;103:339 -48.
16. GambhirSS,CzerninJ,SchwimmerJ,Silverman DH, Coleman RE, Phelps ME. Atabulated summary of the FDGPET literature. J Nucl Med 2001;42:1 -92S.
17. Kelloff GJ, Hoffman JM, Johnson B, et al. Progress and promise of FDG-PET imaging for cancer patient management and oncologic drug development. Clin Cancer Res 2005;11:2785 -808.
18. 18.WeberWA. Use of PET for monitoring cancer therapy and for predicting outcome. J Nucl Med 2005;46: 983-95.
19. 18F]-fluorodeoxyglucose and positron emission tomography: review and 1999 EORTC recommendations. EurJ Cancer 1999;35:1773 -82.
20. Van den Abbeele AD;for the GIST Collaborative PET Study Group (Dana-Farber Cancer Institute, Boston, Massachusetts; OHSU, Portland, Oregon; Helsinki University Central Hospital, Turku University Central Hospital, Finland; Novartis Oncology). F18-FDG-PET provides early evidence of biological response to STI571 in patients with malignant gastrointestinal stromal tumors(GIST). ProcAm SocClin Oncol 2001;20:362a.
21. DemetriGD,vonMehrenM,BlankeCD,etal.Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. N Engl J Med 2002;347: 472-80.
22. Herbst RS, Davies AM, Natale RB, et al. Efficacy and safety of single-agent pertuzumab, a human epidermal receptor dimerization inhibitor, in patients with non small cell lung cancer. Clin Cancer Res 2007;13: 6175-81.
23. Van den Abbeele AD. Abdomen: the lessons of GIST-PETand PET/CT. Oncologist 2008;13:8-13.
24. Van den AbbeeleAD, Ertuk M. FDG-PET to measure responseto targeted therapy: the example of gastrointestinal stromal tumor and imatinib mesylate (Gleevec). In: Mankoff DA, editor. PET Clinics: ResponseTher 2008;3:77 -87.
25. Shankar L, Menkens A, Sullivan D. Molecular imaging in cancer. In: Kaufman HL, editor. Molecular targeting in oncology (cancer drug discovery and development). 1st ed. Totowa (NJ): Humana Press; 2008. p. 675 -92.
26. Desai J, Shankar S, Heinrich MC, et al. Clonal evolution of resistance to imatinib in patients with metastatic gastrointestinal stromal tumors [see comment]. Clin Cancer Res 2007;13:5398-405.
27. 18F-FDG PET as an indicator of therapeutic response in patients in National Cancer Institute trials. J Nucl Med 2006;47: 1059-66.
28. Weiner MA, Leventhal B, Brecher ML, et al. Randomized study of intensive MOPP-ABVD with or without low-dose total-nodal radiation therapy in the treatment of stages IIB, IIIA2, IIIB, and IV Hodgkin's disease in pediatric patients: a Pediatric Oncology Group study. J Clin Oncol 1997;15:2769 -79.
29. Fitz Gerald TJ, Urie M, Ulin K, et al. Processes for quality improvements in radiation oncologyclinical trials. IntJ Radiat Oncol Biol Phys 2008;71:S76 -9.
30. Rischin D, Peters L, O'Sullivan B, et al. Phase III study of tirapazamine, cisplatin and radiation versus cisplatin and radiation for advanced squamous cell carcinoma of the head and neck. J Clin Oncol 2008;26:6008.
31. Benjamin RS, Choi H, Macapinlac H, et al. We should desist using RECIST, at least in GIST. J Clin Oncol 2007;25:1760-4.